We used siRNA-mediated knockdown to deplete Myc in 4 human prostate cancer cell lines- DU145, PC3, LNCaP and CWR22rv1, as well as in the MYC-CaP cell line, which was derived from the Hi-MYC transgenic mouse model [25]. The gene discussed is MYC; the disease is Familial prostate cancer.